Investing.com — Biotech company Moderna said it has asked health regulators in the US and Europe to authorize the use of its COVID-19 vaccine, writes Timesnest.
Moderna shares rose 20.24% on Monday, November 30, to $ 152.74 per share. This level was reached for the first time in the company's history. On the postmarket, biotech papers continued to rise in price, having risen in price by another 6.9%.
«I believe this vaccine will indeed be the turning point of the pandemic. We predict that she may actually prevent serious illness», — said the head of Moderna Stefan Bansel.
A panel of external experts will meet on December 17 to discuss whether there is enough evidence to support the vaccine. Experts to decide if the vaccine can be recommended by the US Food and Drug Administration (FDA) as an emergency drug.
Most likely, the Moderna vaccine is destined to become the second drug ready for use in the US by the end of the year, experts say. Another vaccine so far — co-produced by Pfizer and BioNTech — is already under consideration by regulators who expect to start mass vaccinations next spring or summer.
On Nov. 30, Moderna announced that its mRNA-1273 vaccine is capable of preventing disease 94.1% of use cases. However, it is 100% effective against severe forms of COVID-19..
The text was prepared by Yana Shebalina
— In preparation, materials from Timesnest were used.
Комментарии
Отправить комментарий